Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, DeRosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, Buchbinder SP, Hammer SM, Koblin BA, Pensiero M, Butler C, Moss B, Robinson HL, HVTN 205 Study Group, National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network
J Infect Dis. 2014 210 (1): 99-110

PMID: 24403557 · PMCID: PMC4072895 · DOI:10.1093/infdis/jiu003

MeSH Terms (18)

Adolescent Adult AIDS Vaccines Drug Carriers env Gene Products, Human Immunodeficiency Virus Female HIV-1 HIV Antibodies Humans Male Middle Aged Placebos T-Lymphocytes Time Factors Vaccines, Synthetic Vaccines, Virus-Like Particle Vaccinia virus Young Adult

Connections (1)

This publication is referenced by other Labnodes entities: